# Pembrolizumab After SBRT Versus Pembrolizumab Alone in Advanced NSCLC

> **NCT02492568** · PHASE2 · COMPLETED · sponsor: **The Netherlands Cancer Institute** · enrollment: 92 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** pembrolizumab
- **RADIATION:** Stereotactic Body Radiation Therapy

## Key facts

- **NCT ID:** NCT02492568
- **Lead sponsor:** The Netherlands Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07
- **Primary completion:** 2018-06
- **Final completion:** 2018-06
- **Target enrollment:** 92 (ACTUAL)
- **Last updated:** 2020-08-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02492568

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02492568, "Pembrolizumab After SBRT Versus Pembrolizumab Alone in Advanced NSCLC". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02492568. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*